Genmab A/S
CSE:GMAB

Watchlist Manager
Genmab A/S Logo
Genmab A/S
CSE:GMAB
Watchlist
Price: 1 534.5 DKK -1.35% Market Closed
Market Cap: 101B DKK
Have any thoughts about
Genmab A/S?
Write Note

Genmab A/S
Note Receivable

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Genmab A/S
Note Receivable Peer Comparison

Comparables:
ZEAL
ASND
B
BAVA
F
FLUO
BIOPOR

Competitive Note Receivable Analysis
Latest Figures & CAGR of Competitors

Company Note Receivable CAGR 3Y CAGR 5Y CAGR 10Y
Genmab A/S
CSE:GMAB
Note Receivable
kr77m
CAGR 3-Years
33%
CAGR 5-Years
46%
CAGR 10-Years
27%
Zealand Pharma A/S
CSE:ZEAL
Note Receivable
kr11.7m
CAGR 3-Years
109%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Ascendis Pharma A/S
NASDAQ:ASND
Note Receivable
€2.2m
CAGR 3-Years
9%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
B
Bavarian Nordic A/S
CSE:BAVA
Note Receivable
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
F
Fluoguide AS
STO:FLUO
Note Receivable
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bioporto A/S
CSE:BIOPOR
Note Receivable
kr4.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A

See Also

What is Genmab A/S's Note Receivable?
Note Receivable
77m DKK

Based on the financial report for Jun 30, 2024, Genmab A/S's Note Receivable amounts to 77m DKK.

What is Genmab A/S's Note Receivable growth rate?
Note Receivable CAGR 10Y
27%

Over the last year, the Note Receivable growth was 148%. The average annual Note Receivable growth rates for Genmab A/S have been 33% over the past three years , 46% over the past five years , and 27% over the past ten years .

Back to Top